Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension

Yohei Miura, Masaharu Kataoka, Tomohiro Chiba, Takumi Inami, Hideaki Yoshino, Toru Satoh

研究成果: Article

抜粋

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

元の言語English
ページ(範囲)2676-2677
ページ数2
ジャーナルCirculation Journal
82
発行部数10
DOI
出版物ステータスPublished - 2018 1 1

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

フィンガープリント Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用